UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 非プラチナ製剤ベースの癌化学療法の神経学的合併症の概要 overview of neurologic complications of non platinum cancer chemotherapy
- 2. 若年成人における急性骨髄性白血病に対する導入療法 induction therapy for acute myeloid leukemia in younger adults
- 3. 高齢者における急性骨髄性白血病の治療 treatment of acute myeloid leukemia in older adults
- 4. 全身化学療法に対する輸注反応 infusion reactions to systemic chemotherapy
- 5. 若年成人における急性骨髄性白血病に対する寛解後療法 post remission therapy for acute myeloid leukemia in younger adults
English Journal
- Screening for Marine Natural Products with Potential as Chemotherapeutics for Acute Myeloid Leukemia.
- Hansen E, Andersen JH1.
- Current pharmaceutical biotechnology.Curr Pharm Biotechnol.2016;17(1):71-7.
- Nature is an important source for anti-cancer therapeutics, and nearly half of the currently marketed cancer drugs are derived from natural products. Most of the therapeutic natural products are derived from terrestrial sources, such as paclitaxel, vincristine, epothilones, doxorubicin, etoposide an
- PMID 26278527
- The Use of Nanocarriers in Acute Myeloid Leukaemia Therapy: Challenges and Current Status.
- Sauvage F, Barratt G1, Herfindal L, Vergnaud-Gauduchon J.
- Current pharmaceutical biotechnology.Curr Pharm Biotechnol.2016;17(1):30-41.
- Chemotherapy for AML is hampered by severe side-effects and failure to eliminate all the blasts that eventually leads to relapse. The use of nanosized particulate drug carriers such as liposomes and polymeric nanoparticles has the potential to improve AML therapy by delivering more of the drug to th
- PMID 26278525
- Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
- de Witte T1,2, Suciu S3, Meert L3, Halkes C4, Selleslag D5, Bron D6, Amadori S7, Willemze R4, Muus P8, Baron F9.
- Annals of hematology.Ann Hematol.2015 Dec;94(12):1981-9. doi: 10.1007/s00277-015-2486-9. Epub 2015 Sep 26.
- The primary objective of this trial was to assess the feasibility, toxicity profile, and antitumor activity of gemtuzumab ozogamicin (GO) combined with a chemotherapy remission-induction regimen in adults with untreated high-risk myelodysplastic syndrome (HR-MDS) or secondary acute myeloid leukemia
- PMID 26410352
Japanese Journal
- Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients : significance of cellular nucleoside transporter content
- WRIGHT AM
- Br J Haematol 116, 528-537, 2002
- NAID 30014736430
- Chromatographic properties of cytosine, cytidine and their synthetic analogues
- ROMANOVA D.,NOVOTNY L.
- Journal of chromatography. B, Biomedical applications 675(1), 9-15, 1996-01-12
- NAID 10024551806
Related Pictures
★リンクテーブル★
| リンク元 | 「シタラビン」「アラビノシルシトシン」 |
「シタラビン」
- 英
- cytarabine,Ara-C, ara-C
- 同
- シトシンアラビノシド cytosine arabinoside、アラビノシルシトシン arabinosylcytosine
- 化
- シタラビンオクホスファート cytarabine ocfosphate、塩酸シタラビン cytarabine hydrochloride
- 商
- キロサイド、スタラシド、サイトサール Cytosar、Tarabine
- 関
- cytarabine HC1、代謝拮抗剤
適応
副作用
添付文書
- キロサイドＮ注400mg／**キロサイドＮ注1g
「アラビノシルシトシン」
- 英
- arabinosylcytosine, Ara-C
- 関
- シタラビン